NPC1L1 and diabetes mellitus: In contrast, a large genetic study that assessed life-long exposure to lower LDL-C levels due to carriage of genetic variants of NPC1L1, the target of ezetimibe, showed an increased risk of diabetes and suggested that on glucose homeostasis may be a class effect of LDL-C lowering agents [30].